Continuous Manufacturing Market (Small Molecules and Biologics), 2020-2030"

AMERICAN CANYON, Calif. - May 5, 2020 - PRLog -- The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.

Key Market Insights

Around 65 companies claim to have expertise in continuous manufacturing of small molecule / biologic drugs

The continuous manufacturing market landscape is dominated by well-established players (founded before 1990), which represent more than 50% of the total number of stakeholders. Amongst these, close to 55% players are headquartered in Europe, followed by those based in North America (36%).

Close to 45 partnerships were inked between 2013 and 2019

More than 55% of such agreements were focused on technology improvements and research. Further, 58% of the recent partnerships were established for drug product manufacturing, while the remaining were focused on the production of API / intermediate.

Nearly 55 expansion initiatives were undertaken in the period 2013-2020 (till January)

Most such projects (55%) were reported to be focused on establishment of a new facility / plant, followed by those carried out for incorporating continuous manufacturing technologies (28%) into the existing facilities of different companies. It is worth mentioning that more than 45% of the total number of expansions captured in the report, were observed to have been carried out in Europe.

Around 165 grants were awarded to support ongoing R&D activities in continuous manufacturing, between 2014 and 2019

Collectively, the capital amount awarded to support R&D in this field was estimated to be worth USD 69.7 million. It is worth noting that 35 grants were awarded in 2019 alone. A significant proportion of grants identified in the report (22%) were awarded to the Illinois Institute of Technology, followed by those awarded to Purdue University (12%).

Several patents have been filed / granted related to continuous manufacturing

It is worth noting that majority of patents (187) were filed / granted in 2019; of these, close to 75% represented the intellectual capital of industry players. Further, around 50% of the total number of patents were filed / granted in North America, followed by Europe (35%).

Over 70% of the installed continuous manufacturing capacity belongs to established players

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com